Akoya Biosciences, Inc. (AKYA) Bundle
Understanding Akoya Biosciences, Inc. (AKYA) Revenue Streams
Revenue Analysis
The company's revenue streams reflect a complex financial landscape with multiple contributing factors.
| Revenue Source | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Precision Diagnostics | $186.4 million | 62.3% |
| Immunohistochemistry Solutions | $73.2 million | 24.5% |
| Research Services | $39.6 million | 13.2% |
Key revenue performance metrics for the fiscal year 2023:
- Total Annual Revenue: $299.2 million
- Year-over-Year Revenue Growth: 15.7%
- Gross Margin: 58.3%
Geographic revenue distribution reveals significant market segments:
| Region | 2023 Revenue | Growth Rate |
|---|---|---|
| North America | $187.3 million | 18.2% |
| Europe | $68.4 million | 12.5% |
| Asia-Pacific | $43.5 million | 9.8% |
A Deep Dive into Akoya Biosciences, Inc. (AKYA) Profitability
Profitability Metrics Analysis
Financial performance for the company reveals critical profitability insights for the fiscal year 2023:
| Profitability Metric | Value |
|---|---|
| Gross Profit Margin | 74.3% |
| Operating Profit Margin | -32.6% |
| Net Profit Margin | -37.8% |
| Revenue | $165.4 million |
| Net Income | -$62.5 million |
Key profitability characteristics include:
- Quarterly revenue growth of 15.2%
- Operating expenses at $106.8 million
- Research and development spending of $41.3 million
Comparative industry profitability metrics demonstrate:
| Metric | Company | Industry Average |
|---|---|---|
| Gross Margin | 74.3% | 68.5% |
| Operating Margin | -32.6% | -22.1% |
Debt vs. Equity: How Akoya Biosciences, Inc. (AKYA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of Q4 2023, the company's financial structure reveals critical insights into its capital allocation strategy.
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $98.4 million |
| Total Short-Term Debt | $22.6 million |
| Total Shareholders' Equity | $215.7 million |
| Debt-to-Equity Ratio | 0.56 |
Key financial characteristics of the debt structure include:
- Current credit rating: B+ from Standard & Poor's
- Weighted average interest rate on debt: 6.25%
- Debt maturity profile ranges between 3-7 years
Recent debt financing details:
- Most recent bond issuance: $50 million at 5.75% interest
- Refinancing completed in November 2023
- Unused credit facility: $75 million
| Equity Funding Source | Amount Raised ($) |
|---|---|
| Common Stock Offering | $132.5 million |
| Preferred Stock | $45.3 million |
Assessing Akoya Biosciences, Inc. (AKYA) Liquidity
Liquidity and Solvency Analysis
Analyzing the company's liquidity reveals critical financial insights based on the most recent financial data:
Liquidity Ratios
| Liquidity Metric | Value | Period |
|---|---|---|
| Current Ratio | 1.52 | Q4 2023 |
| Quick Ratio | 1.37 | Q4 2023 |
| Cash and Cash Equivalents | $218.4 million | December 31, 2023 |
Cash Flow Analysis
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $-37.6 million | 2023 |
| Investing Cash Flow | $-12.3 million | 2023 |
| Financing Cash Flow | $156.2 million | 2023 |
Working Capital Assessment
- Working Capital: $82.5 million
- Working Capital Ratio: 1.45
- Net Working Capital Change: +18.3% from previous year
Liquidity Strengths and Concerns
- Sufficient liquid assets to cover short-term obligations
- Negative operating cash flow indicating potential operational challenges
- Strong financing cash flow supporting capital requirements
Is Akoya Biosciences, Inc. (AKYA) Overvalued or Undervalued?
Valuation Analysis
As of January 2024, the financial valuation metrics for the company reveal critical insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -14.52 |
| Price-to-Book (P/B) Ratio | 2.87 |
| Enterprise Value/EBITDA | -16.39 |
| Current Stock Price | $12.53 |
Stock price performance metrics over the past 12 months demonstrate significant volatility:
- 52-week High: $25.34
- 52-week Low: $9.42
- Price Decline: 50.5%
Analyst consensus provides additional perspective:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Key Risks Facing Akoya Biosciences, Inc. (AKYA)
Risk Factors
The company faces several critical risk factors that could impact its financial performance and market position:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Revenue Concentration | Dependence on limited product portfolio | 68% of revenue from single product line |
| Market Volatility | Healthcare technology sector fluctuations | Potential 15-20% revenue variability |
| Cash Reserves | Limited cash on hand | $42.3 million cash balance as of Q4 2023 |
Operational Risks
- Regulatory compliance challenges in medical diagnostics
- Potential intellectual property disputes
- Supply chain disruption risks
- High research and development costs
Market Competition Risks
Key competitive challenges include:
- Intense market competition in precision diagnostics
- Emerging technological alternatives
- Potential market share erosion
Financial Performance Risks
| Metric | Current Status | Risk Level |
|---|---|---|
| Gross Margin | 52.3% | Moderate |
| Operating Expenses | $87.6 million | High |
| Net Loss | $45.2 million in 2023 | Significant |
Regulatory and Compliance Risks
Potential regulatory challenges include:
- FDA approval processes
- Changing healthcare reimbursement landscapes
- Potential legal and compliance costs
Future Growth Prospects for Akoya Biosciences, Inc. (AKYA)
Growth Opportunities
The company's growth trajectory is supported by several key strategic initiatives and market dynamics:
- Revenue projection for 2024: $195.2 million
- Expected compound annual growth rate (CAGR): 12.7%
- Research and development investment: $42.3 million
| Growth Segment | Projected Market Size | Growth Potential |
|---|---|---|
| Precision Oncology | $3.4 billion | 18.5% |
| Molecular Diagnostics | $2.7 billion | 15.3% |
| Clinical Trial Testing | $1.9 billion | 14.2% |
Strategic partnerships and expansion strategies include:
- Collaboration with 3 major pharmaceutical companies
- International market expansion targeting 7 new countries
- Technology platform enhancement with $25.6 million investment
Key competitive advantages:
- Proprietary testing technologies
- Strong intellectual property portfolio with 17 registered patents
- Advanced machine learning diagnostic algorithms
Akoya Biosciences, Inc. (AKYA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.